VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
AstraZeneca PLC vs Brookfield Infrastructure Partners L.P.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisBrookfield Infrastructure Partners L.P.
BIP · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Brookfield Infrastructure Partners L.P.'s moat claims, evidence, and risks.
View BIP analysisComparison highlights
- Moat score gap: Brookfield Infrastructure Partners L.P. leads (74 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Brookfield Infrastructure Partners L.P. has 4 segments.
- Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Strong vs Moderate.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Brookfield Infrastructure Partners L.P. has 4 across 3.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Brookfield Infrastructure Partners L.P.
Utilities
Regulated and contracted utility infrastructure (electric transmission, gas pipelines/distribution, metering and residential energy services)
Global
Regulators and contracted counterparties; residential and commercial end-users via utility networks
Owner-operator of regulated networks and contracted utility assets
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
AstraZeneca PLC strengths
Brookfield Infrastructure Partners L.P. strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Brookfield Infrastructure Partners L.P. segments
Full profile >Utilities
Quasi-Monopoly
Transport
Oligopoly
Midstream
Oligopoly
Data
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.